Candi5V01 A FTIH Phase I/II Randomized and Controlled Study to Test Safety, Immunogenicity and Preliminary Efficacy of a Pentavalent Bioconjugate Vaccine (Candi5V) Against Candida in Women With Recurrent Vulvovaginal Candidiasis
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Candi 5V (Primary)
- Indications Vulvovaginal candidiasis
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors LimmaTech Biologics
Most Recent Events
- 10 Feb 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 18 Dec 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 18 Dec 2024 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.